Unique ID issued by UMIN | UMIN000036793 |
---|---|
Receipt number | R000041924 |
Scientific Title | Clinical data over long term with sitagliptin treatment for type 2 diabetes patients in our hospital |
Date of disclosure of the study information | 2019/05/19 |
Last modified on | 2020/01/16 08:45:02 |
Clinical data over long term with sitagliptin treatment for type 2 diabetes patients in our hospital
Clinical data over long term with sitagliptin treatment for type 2 diabetes patients in our hospital
Clinical data over long term with sitagliptin treatment for type 2 diabetes patients in our hospital
Clinical data over long term with sitagliptin treatment for type 2 diabetes patients in our hospital
Japan |
type 2 diabetes mellitus
Endocrinology and Metabolism |
Others
NO
Administration of sitagliptin is expected not only to improve blood glucose but also to have a renal protection effect. However, there are not many reports on the long-term effects of sitagliptin in Japan.Therefore, we explore the effects on glycemic control and renal protection effect in patients with type 2 diabetes treated with sitagliptin for more than 5years.
Safety,Efficacy
Exploratory
Pragmatic
Not applicable
HbA1c, Urinary albumin
1. Efficacy and safety of sitagliptin single use
2. Safety in the elderly
3. Safety of patients using insulin
Observational
20 | years-old | <= |
90 | years-old | >= |
Male and Female
1) Outpatients
2) over 20 years old
3) T2DM
4) eGFR over 30 mL/min/1.73 m2
5) Diet and exercise therapies are well performed
6) Patients who are suspected good-compliant
7) Understanding of the study procedures and agreement to participate in the study, by giving written informed consent
1) Patients suspected of having secondary diabetes (ex. endocrine disease, drug-induced or liver disease)
2) Females who are pregnant or who intend to become pregnant within the study
3) Severe hepatic disease, malignancy, a history of gastrectomy and/or positive for HIV
4) Contraindication with sitagliptin
5) Patient who disqualified from the study by the investigator for any reason other than given above.
300
1st name | Yasuhiro |
Middle name | |
Last name | Iijima |
Tokyo Medical University
Department of Diabetes, Endocrinology and Metabolism
160-0023
6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo
03-3342-6111
yasuhiro.iijima1203@gmail.com
1st name | Yasuhiro |
Middle name | |
Last name | Iijima |
Manda Memorial Hospital
Diabetes Center
060-0062
Minami 2, Nishi 1, Chuo-ku, Sapporo
011-231-4032
yasuhiro.iijima1203@gmail.com
Manda memorial hospital
none
Self funding
Manda Memorial Hospital
Minami 2, Nishi 1, Chuo-ku, Sapporo
011-231-4032
yasuhiro.iijima1203@gmail.com
NO
萬田記念病院(北海道)
2019 | Year | 05 | Month | 19 | Day |
Unpublished
400
Completed
2018 | Year | 12 | Month | 01 | Day |
2019 | Year | 04 | Month | 19 | Day |
2018 | Year | 12 | Month | 01 | Day |
2019 | Year | 04 | Month | 01 | Day |
This study examines the retrospective effectiveness of medical records from patients with type 2 diabetes mellitus during outpatient visits to our hospital who have been dosed with sitagliptin during 2009-2013. Evaluation items are determined on the basis of HbA1c, microalbuminuria, and progression of complications. Statistical analysis is performed on the obtained data to evaluate the effect. And we will consider the secondary effects from the following three points.
(1) Patients who continued to use sitagliptin alone, (2) elderly patients aged 65 years or older, and (3) patients with combined insulin
2019 | Year | 05 | Month | 19 | Day |
2020 | Year | 01 | Month | 16 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041924
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |